title: H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts.
abstract: Male F344 rats were fed 0.2% N-[4-(5-nitro-2-furyl)-2-thiazoly]formamide for 6 weeks and then fed 3% or 5% sodium saccharin, 5% sodium ascorbate, 3.12% calcium saccharin, 1.34% sodium chloride, 5.2% calcium saccharin plus 1.34% sodium chloride, or basal diet alone for 72 weeks. Protein and DNA were extracted from 89 bladder tumors [87 transitional cell carcinomas (TCC), 1 papilloma, and 1 sarcoma] from 86 rats p21 expression was examined by Western blotting using a monoclonal antibody against p21 (NCC-RAS-004). H-ras mutations in exons 1 and 2 were examined by direct sequencing of DNA amplified by polymerase chain reaction. Sequencing results demonstrated mutations at codon 61 (CAA to CGA in 15 TCCs; CAA to CTA in 2 TCCs), at codon 12 (GGA to TGG in 1 TCC), and at codon 13 (GGC to GTC in 3 TCCs). Mutations at codon 61 were confirmed by faster mobility of the p21 band in Western blots. The level of p21 expression varied among samples, but many TCCs appeared to express more p21 than controls. The overall incidence of H-ras mutations was 24.4% (21 of 86 rats). The type of chemical used for the promoting phase had essentially no effect on H-ras mutation, suggesting that the effects observed were related to FANFT administration. The frequency of H-ras mutation in each group was negatively related to the incidence of carcinoma (r = -0.85; P less than 0.01). Two groups of tumors (with or without the mutated ras gene) were compared for tumor size (reflected by the bladder weight), histological grading, and the presence of invasion. The size of tumors with mutated ras was significantly smaller than those without mutated ras. There was no difference in the histological grading between the two groups. Although not statistically significant, histological invasion was more frequently observed in tumors with mutated ras (14.3%) than in tumors without mutation (3.1%).
authors.affiliation: Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-3135.
authors.forename: T
authors.initials: T
authors.lastname: Masui
authors.forename: A M
authors.initials: AM
authors.lastname: Mann
authors.forename: T L
authors.initials: TL
authors.lastname: Macatee
authors.forename: T
authors.initials: T
authors.lastname: Okamura
authors.forename: E M
authors.initials: EM
authors.lastname: Garland
authors.forename: H
authors.initials: H
authors.lastname: Fujii
authors.forename: J C
authors.initials: JC
authors.lastname: Pelling
authors.forename: S M
authors.initials: SM
authors.lastname: Cohen
mesh_terms: D000818:Animals; D001205:Ascorbic Acid; D001483:Base Sequence; D015153:Blotting, Western; D002273:Carcinogens; D002277:Carcinoma / Q000139:chemically induced / Q000235:genetics*; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D005200:FANFT; D011905:Genes, ras; D008297:Male; D009154:Mutation; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D051381:Rats; D011916:Rats, Inbred F344; D012439:Saccharin; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000235:genetics*
chemical_list: D002273:Carcinogens; D004273:DNA, Neoplasm; D005200:FANFT; D016283:Proto-Oncogene Proteins p21(ras); D012439:Saccharin; D001205:Ascorbic Acid